The good news: the indigenous Caucasus is also effective against the double-mutant variant of the Corona, which is wreaking havoc in the country.

New delhi date. 21 April 2021, Wednesday

India Biotech and ICMR have released data on the third phase trial of Corona vaccine covexin. As such the clinical efficacy of this vaccine is 78% and 100% effective against severe coronary heart disease. However, final data on covacin may come in June.

Not only that, but new research from ICMR has shown that the indigenous corona vaccine covacin made in India is effective against all variants of SARS-Cov-2. The double mutant strain is the second wave of corona vaccine in India. Covexin is also effective against double mutant strains.

The Phase-3 trial involved 25,000 people between the ages of 18-98. This includes 10 percent of people over the age of 60. During the trial, these people were given a second dose of the vaccine 14 days later. The National Institute of Virology has successfully isolated several variants of the SARS-Cov-2 virus. These include Brazil variant B.1.1.28, UK variant B.1.1.7, South African variant B.1.351.

Krishna Bio, Chief of Bharat Biotech, said that Covexin has proved to be very effective against SARS-Cov-2. Covexin has a record performance in emergency use. Has met world-class criteria, and released final trial data.